1. |
Wu MY, Yiang GT, Liao WT, et al. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem, 2018, 46(4): 1650-1667.
|
2. |
Zhou H, Zhou D, Lu J, et al. Effects of pre-cardiopulmonary bypass administration of dexmedetomidine on cardiac injuries and the inflammatory response in valve replacement surgery with a sevoflurane postconditioning protocol: a pilot study. J Cardiovasc Pharmacol, 2019, 74(2): 91-97.
|
3. |
Chang JC, Lien CF, Lee WS, et al. Intermittent hypoxia prevents myocardial mitochondrial Ca2+ overload and cell death during ischemia/reperfusion: the role of reactive oxygen species. Cells, 2019, 8(6): 564.
|
4. |
Salameh A, Dhein S, Mewes M, et al. Anti-oxidative or anti-inflammatory additives reduce ischemia/reperfusions injury in an animal model of cardiopulmonary bypass. Saudi J Biol Sci, 2020, 27(1): 18-29.
|
5. |
Ergün S, Dedemoğlu M, Rabuş MB, et al. Short-term results of flanged Bentall de Bono and valve-sparing David V procedures for the treatment of aortic root aneurysms. Cardiovasc J Afr, 2018, 29(4): 241-245.
|
6. |
Salgado FM, Barral M, Barrucand L, et al. A randomized blinded study of the left ventricular myocardial performance index comparing epinephrine to levosimendan following cardiopulmonary bypass. PLoS One, 2015, 10(12): e0143315.
|
7. |
Danielsson T, Schreyer H, Woksepp H, et al. Two-peaked increase of serum myosin heavy chain-α after triathlon suggests heart muscle cell death. BMJ Open Sport Exerc Med, 2019, 5(1): e000486.
|
8. |
Granjon D, Bonny O, Edwards A. Coupling between phosphate and calcium homeostasis: a mathematical model. Am J Physiol Renal Physiol, 2017, 313(6): F1181-F1199.
|
9. |
Ranieri M. Renal Ca2+ and water handling in response to calcium sensing receptor signaling: physiopathological aspects and role of CaSR-regulated microRNAs. Int J Mol Sci, 2019, 20(21): 5341.
|
10. |
Schmitt CP, Huber D, Mehls O, et al. Altered instantaneous and calcium-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. J Am Soc Nephrol, 1998, 9(10): 1832-1844.
|
11. |
Koc H, Hoser H, Akdag Y, et al. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study. Int Urol Nephrol, 2019, 51(7): 1261-1270.
|
12. |
Chandran M, Wong J. Secondary and tertiary hyperparathyroidism in chronic kidney disease: an endocrine and renal perspective. Indian J Endocrinol Metab, 2019, 23(4): 391-399.
|
13. |
Stedman T, Chew P, Truran P, et al. Modification, validation and implementation of a protocol for post-thyroidectomy hypocalcaemia. Ann R Coll Surg Engl, 2018, 100(2): 135-139.
|
14. |
Liu Z, Su G, Guo X, et al. Dietary interventions for mineral and bone disorder in people with chronic kidney disease. Cochrane Database Syst Rev, 2015, 16(9): CD010350.
|
15. |
Brown SJ, Ruppe MD, Tabatabai LS. The parathyroid gland and heart disease. Methodist Debakey Cardiovasc J, 2017, 13(2): 49-54.
|
16. |
D’Amour P. Circulating PTH molecular forms: what we know and what we don’t. Kidney Int Suppl, 2006(102): S29-S33.
|
17. |
Cozzolino M, Messa P, Brancaccio D, et al. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort. Blood Purif, 2014, 38(1): 37-45.
|